Research programme: gastrointestinal disorders therapeutics - Scioto Biosciences
Latest Information Update: 28 Aug 2023
At a glance
- Originator Scioto Biosciences
- Class Antibacterials; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Clostridium difficile infections; Necrotising enterocolitis
Most Recent Events
- 13 Jul 2023 Preclinical trials in Clostridium difficile infections in USA (unspecified route) (Scioto Biosciences pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Necrotising enterocolitis in USA (unspecified route) (Scioto Biosciences pipeline, July 2023)